Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

In the wake of an unfavorable advisory committee meeting in September, Intercept Pharmaceuticals’ bid to win full approval ...

Despite generic headwinds to Xarelto and challenges across different sectors of the conglomerate suggesting “twists and turns ...

After a series of acquisitions and an activist investor’s accusation of overspending, Pfizer is exploring an opportunity to ...

AstraZeneca on Tuesday revealed that it’s adding $2 billion more to its current outlay in the U.S., representing a total ...

Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at ...

PhRMA is pushing to get pharmacy benefit manager (PBM) reform over the line in Congress’ lame-duck session, using its first ...

With biomanufacturing often a limiting factor for drug developers, Canada’s Future Fields is heralding its bug-based approach ...

In a bid to streamline viral vector manufacturing, Thermo Fisher is charting another round of layoffs this year—and ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

Havas Health has appointed Anna Maria Marra CEO of Europe. Marra is joining the healthcare agency after a 22-year run at ...

Despite China’s investigations into insurance fraud, allegedly illegal importation of unapproved drugs and improper ...